Use of Clinical Pharmacology in Slowing the Myopia Epidemic
Clinical Pharmacology & Therapeutics · 2026-09 · 120 (3) · 592-593
DOI: 10.1002/cpt.70364 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 15.06.2026. Verfasst von Gary D Novack. Beteiligte Einrichtung: PharmaLogic Development, Inc., San Rafael, California, USA. Hauptthemen laut MEDLINE: Atropine, Myopia, Pharmacology, Clinical. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Myopia (nearsightedness) is in epidemic proportions in the world today. The eyecare community has long been desirous of pharmacological treatments to slow myopic progression. Most recently, two proprietary formulations of low‐dose atropine were approved. In this article, the author summarizes the challenge to develop therapies for a chronic, preventative, and pediatric treatment, and how clinical pharmacologists' knowledge of pharmaceutics, pharmacokinetics, and therapeutics can optimize the development of therapies to slow myopic progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- PharmaLogic Development, Inc., San Rafael, California, USA.
- Department of Ophthalmology & Vision Science, University of California, Davis, School of Medicine, Sacramento, California, USA.
ORCID-Profile: Gary D Novack
Zitieren
APA
Novack, G. D. (2026). Use of Clinical Pharmacology in Slowing the Myopia Epidemic. Clinical Pharmacology & Therapeutics, 120(3), 592-593. https://doi.org/10.1002/cpt.70364
Vancouver
Novack GD. Use of Clinical Pharmacology in Slowing the Myopia Epidemic. Clinical Pharmacology & Therapeutics. 2026;120(3):592-593. doi:10.1002/cpt.70364
BibTeX
@article{Novack2026,
author = {Novack, Gary D},
title = {Use of Clinical Pharmacology in Slowing the Myopia Epidemic},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
volume = {120},
number = {3},
pages = {592--593},
doi = {10.1002/cpt.70364}
}
EUVIMED